Premium
Identification and characterization of C106R, a novel mutation in the DNA‐binding domain of GCMB, in a family with autosomal‐dominant hypoparathyroidism
Author(s) -
Yi HyonSeung,
Eom Young Sil,
Park Ie Byung,
Lee Sangho,
Hong Suntaek,
Jüppner Harald,
Mannstadt Michael,
Lee Sihoon
Publication year - 2012
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.2011.04256.x
Subject(s) - transactivation , mutant , biology , dna binding domain , electrophoretic mobility shift assay , microbiology and biotechnology , mutation , genomic dna , wild type , dna , transcription factor , gene , genetics
Summary Overview Glial cells missing B (GCMB) is a transcription factor that is expressed in the parathyroid hormone (PTH)‐secreting cells of the parathyroid glands. Several mutations in GCMB have been reported to cause hypoparathyroidism (HP). We identified a family with two individuals in two generations (mother and son), who are affected by autosomal‐dominant hypoparathyroidism (AD‐HP). A novel heterozygous mutation in exon 2 of GCMB was identified in both affected individuals that changes cysteine at position 106 of the putative DNA‐binding domain of GCMB to arginine (C106R). Methods We performed mutational analysis of the genes encoding GCMB, pre‐pro PTH, GATA3 and CaSR using polymerase chain reaction (PCR)‐amplified genomic DNA. The identified GCMB mutant was characterized by functional studies including nuclear localization, electrophoretic mobility shift assays (EMSA) and luciferase reporter assays, and homology modelling was performed to generate a three‐dimensional structural model for the DNA‐binding domain of GCMB to predict the structural consequences of the identified mutation. Results The C106R mutant of GCMB failed to interact with the DNA consensus recognition motif, as determined by EMSA. Furthermore, in comparison with wild‐type GCMB, the C106R mutant demonstrated reduced transactivation in luciferase reporter assays; however, the mutant GCMB failed to reduce the activity of the wild‐type protein. Consistent with the EMSA findings, homology modelling analysis suggested that replacement of cysteine 106 with arginine would interfere with DNA binding. Conclusions We have identified a novel GCMB mutation that may explain AD‐HP in our family. However, the exact mechanism by which this heterozygous mutation leads to the disease in the described family remains to be elucidated.